OR10A5

Across TCGA pan-cancer cohorts, OR10A5 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated OR10A5 data layer compared with 10 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher OR10A5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR10A5 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

SCLC, ESCA, and LGG are the cancer types where OR10A5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.082	0.708	<.001	36	view →
ESCA	OS	Median	II,III,IV	0.206	0.686	.004	12	view →
LGG	OS	Median	All	0.214	0.889	<.001	6	view →
BLCA	DFS	Median	III,IV	0.121	0.488	.020	6	view →
UCEC	DFS	Median	All	1.000	0.635	.029	4	view →
SKCM	OS	Median	II,III,IV	0.953	0.830	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

OR10A5–SCLC (OS)

Open the SCLC breakdown →